Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 70.4 Thousand EUR | -29.86% |
| 2022 | 100.38 Thousand EUR | 32.84% |
| 2021 | 75.56 Thousand EUR | -25.94% |
| 2020 | 102.03 Thousand EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| 2015 | - EUR | 0.0% |
| 2014 | - EUR | -100.0% |
| 2013 | 25.2 Thousand EUR | -80.58% |
| 2012 | 129.74 Thousand EUR | -40.6% |
| 2011 | 218.42 Thousand EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 69.79 Thousand EUR | 0.0% |
| 2024 Q2 | 21.19 Million EUR | 0.0% |
| 2024 Q3 | 21.18 Million EUR | 0.0% |
| 2023 Q3 | 99.15 Thousand EUR | -22.18% |
| 2023 Q2 | 127.41 Thousand EUR | 59.25% |
| 2023 Q1 | 80 Thousand EUR | -20.3% |
| 2023 FY | 70.4 Thousand EUR | -29.86% |
| 2023 Q4 | 70.4 Thousand EUR | -28.99% |
| 2022 Q4 | 100.38 Thousand EUR | -0.26% |
| 2022 Q3 | 100.64 Thousand EUR | 94.25% |
| 2022 FY | 100.38 Thousand EUR | 32.84% |
| 2022 Q1 | 55.36 Thousand EUR | -26.73% |
| 2022 Q2 | 51.81 Thousand EUR | -6.42% |
| 2021 Q1 | 79.24 Thousand EUR | -22.33% |
| 2021 Q4 | 75.56 Thousand EUR | 123.08% |
| 2021 Q2 | 56.73 Thousand EUR | -28.41% |
| 2021 FY | 75.56 Thousand EUR | -25.94% |
| 2021 Q3 | 33.87 Thousand EUR | -40.29% |
| 2020 Q4 | 102.03 Thousand EUR | -18.77% |
| 2020 Q1 | 163.21 Thousand EUR | 0.0% |
| 2020 FY | 102.03 Thousand EUR | 0.0% |
| 2020 Q2 | 138.67 Thousand EUR | -15.03% |
| 2020 Q3 | 125.6 Thousand EUR | -9.43% |
| 2019 Q2 | - EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q3 | - EUR | 0.0% |
| 2019 Q4 | - EUR | 0.0% |
| 2018 FY | - EUR | 0.0% |
| 2018 Q4 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 Q1 | - EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2014 Q1 | 13.34 Thousand EUR | -47.05% |
| 2014 Q3 | - EUR | -100.0% |
| 2014 Q2 | 6593.00 EUR | -50.6% |
| 2014 FY | - EUR | -100.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2013 Q3 | 39.45 Thousand EUR | -26.15% |
| 2013 Q2 | 53.42 Thousand EUR | -41.89% |
| 2013 Q1 | 91.94 Thousand EUR | -29.14% |
| 2013 FY | 25.2 Thousand EUR | -80.58% |
| 2013 Q4 | 25.2 Thousand EUR | -36.12% |
| 2012 Q3 | 95.2 Thousand EUR | -3.98% |
| 2012 FY | 129.74 Thousand EUR | -40.6% |
| 2012 Q1 | 84.99 Thousand EUR | -61.09% |
| 2012 Q2 | 99.15 Thousand EUR | 16.65% |
| 2012 Q4 | 129.74 Thousand EUR | 36.29% |
| 2011 Q3 | 257.01 Thousand EUR | 92.71% |
| 2011 Q1 | 67.86 Thousand EUR | -17.4% |
| 2011 FY | 218.42 Thousand EUR | 0.0% |
| 2011 Q4 | 218.42 Thousand EUR | -15.01% |
| 2011 Q2 | 133.36 Thousand EUR | 96.52% |
| 2010 Q1 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | 82.15 Thousand EUR | -14.68% |
| 2010 Q3 | 96.28 Thousand EUR | -12.66% |
| 2010 Q2 | 110.25 Thousand EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | 99.963% |
| CureVac N.V. | 36.81 Million EUR | 99.809% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 99.981% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 99.981% |
| BRAIN Biotech AG | 25.19 Million EUR | 99.721% |
| Formycon AG | 7.81 Million EUR | 99.099% |
| Medigene AG | 2.03 Million EUR | 96.542% |